Download Free Phenotypic Screening In The 21st Century Book in PDF and EPUB Free Download. You can read online Phenotypic Screening In The 21st Century and write the review.

In the genomic era of 1990s-2000s, pharmaceutical research moved to target-based drug discovery which enabled development of a number of small molecule drugs against a wide range of diseases. In many cases however, drugs that arose from genomics failed, questioning the validity of the targets and the suitability of target-based drug discovery as an optimal strategy for all disease states. For monogenic diseases, target-based approaches may be well-suited to the identification of novel therapies. Most diseases, however, are caused by a combination of several genetic and environmental factors and are likely to require simultaneous modulation of multiple molecular targets/pathways for successful treatment. For such diseases, reductionist approaches focusing on individual targets rather than biological networks are unlikely to succeed and new drug development strategies are required. In search of more successful approaches, the pharmaceutical industry is moving towards phenotypic screening beyond individual genes/targets. However, this requires rethinking of diseases and drug discovery approaches from a network and systems biology perspective. Since returning to the pre-genomics era of screening drug candidates in laborious animal models is not a feasible solution, the industry needs to evolve a new paradigm of phenotypic drug discovery within the context of systems biology. Such a paradigm must combine physiologically and disease relevant biological substrates with sufficient throughput, operational simplicity and statistical vigour. Biomarker strategies for translational medicine, as well as preclinical safety and selectivity assessments, would also need to be revised to adapt to the target agnostic style. This focused issue aims to discuss strategies, key concepts and technologies related to systems-based approaches in drug development. Design and implementation of innovative biological assays, featuring multiple target strategies, and rational drug design in the absence of target knowledge during the early drug discovery are illustrated with examples. Specific topics include: • The need for systems-based approaches in drug development • Phenotypic screening strategies • Compound libraries (natural product inspired compound collections) • Target deconvolution and identification • Target agnostic lead discovery and optimization • Multi-target approaches and decoding the phenotype (understanding biological interactions and multiscale systems modelling) • Translational aspects • Early evaluation of selectivity and safety in a target agnostic manner
Advances in molecular biology and toxicology are paving the way for major improvements in the evaluation of the hazards posed by the large number of chemicals found at low levels in the environment. The National Research Council was asked by the U.S. Environmental Protection Agency to review the state of the science and create a far-reaching vision for the future of toxicity testing. The book finds that developing, improving, and validating new laboratory tools based on recent scientific advances could significantly improve our ability to understand the hazards and risks posed by chemicals. This new knowledge would lead to much more informed environmental regulations and dramatically reduce the need for animal testing because the new tests would be based on human cells and cell components. Substantial scientific efforts and resources will be required to leverage these new technologies to realize the vision, but the result will be a more efficient, informative and less costly system for assessing the hazards posed by industrial chemicals and pesticides.
The first broad survey of these two fields, this book deleniates a framework for integrating advances in human genetics into public health practice.
Bioactive compounds produced by natural sources, such as plants, microbes, endophytic fungi, etc., can potentially be applied in various fields, including agriculture, biotechnology and biomedicine. Several bioactive compounds have proved to be invaluable in mediating plant-microbe interactions, and promoting plant growth and development. Due to their numerous health-promoting properties, these compounds have been widely used as a source of medication since ancient times. However, there is an unprecedented need to meet the growing demand for natural bioactive compounds in the flavor and fragrance, food, and pharmaceutical industries. Moreover, discovering new lead molecules from natural sources is essential to overcoming the rising number of new diseases. In this regard, natural bioactive compounds hold tremendous potential for new drug discovery. Therefore, this field of research has become a vital area for researchers interested in understanding the chemistry, biosynthetic mechanisms, and pharmacological activities of these bioactive metabolites. This book describes the basics of bioactive plant compounds, their chemical properties, and their pharmacological biotechnological properties with regard to various human diseases and applications in the drug, cosmetics and herbal industries. It offers a valuable asset for all students, educators, researchers, and healthcare experts involved in agronomy, ecology, crop science, molecular biology, stress physiology, and natural products.
Now more than ever, biology has the potential to contribute practical solutions to many of the major challenges confronting the United States and the world. A New Biology for the 21st Century recommends that a "New Biology" approach-one that depends on greater integration within biology, and closer collaboration with physical, computational, and earth scientists, mathematicians and engineers-be used to find solutions to four key societal needs: sustainable food production, ecosystem restoration, optimized biofuel production, and improvement in human health. The approach calls for a coordinated effort to leverage resources across the federal, private, and academic sectors to help meet challenges and improve the return on life science research in general.
Thoroughly reviews our current understanding of malarial biology Explores the subject with insights from post-genomic technologies Looks broadly at the disease, vectors of infection, and treatment and prevention strategies A timely publication with chapters written by global researchers leaders
This book is a comprehensive and up-to-date resource on the use of regenerative medicine for the treatment of cardiovascular disease. It provides a much-needed review of the rapid development and evolution of bio-fabrication techniques to engineer cardiovascular tissues as well as their use in clinical settings. The book incorporates recent advances in the biology, biomaterial design, and manufacturing of bioengineered cardiovascular tissue with their clinical applications to bridge the basic sciences to current and future cardiovascular treatment. The book begins with an examination of state-of-the-art cellular, biomaterial, and macromolecular technologies for the repair and regeneration of diseased heart tissue. It discusses advances in nanotechnology and bioengineering of cardiac microtissues using acoustic assembly. Subsequent chapters explore the clinical applications and translational potential of current technologies such as cardiac patch-based treatments, cell-based regenerative therapies, and injectable hydrogels. The book examines how these methodologies are used to treat a variety of cardiovascular diseases including myocardial infarction, congenital heart disease, and ischemic heart injuries. Finally, the volume concludes with a summary of the most prominent challenges and perspectives on the field of cardiovascular tissue engineering and clinical cardiovascular regenerative medicine. Cardiovascular Regenerative Medicine is an essential resource for physicians, residents, fellows, and medical students in cardiology and cardiovascular regeneration as well as clinical and basic researchers in bioengineering, nanomaterial and technology, and cardiovascular biology.
The 20th century has seen improvements in both public health and disease prevention which, in turn, have had a dramatic impact on our lives. Success in preventing infection by vaccination and treating infection with antibiotics led some to believe that infectious disease was a thing of the past. However, the adaptability of pathogens and the emergence of new diseases has presented microbiologists with a fresh set of challenges as we enter the new millennium. While celebrating past successes and highlighting developing problems, this volume aims to address some of the issues facing microbiologists in the future. Covering a wide range of topics, it will provide an invaluable resource for microbiologists and an excellent reference for advanced students.
Exploring plant genetic resources is crucial in a time when food security has been a critical topic worldwide due to crop shortages and the impact of climate change. This new book, Plant Genetic Resources for the 21st Century: The OMICS Era, presents the practical advancements in genomics, epigenetics, metabolomics, and phenomics from the point of view of researchers and scientists working in the field of genebanks, genetics resources, and germplasm for enabling plant breeding and adaptation to a changing climate. The book highlights the importance of genebanks as centers of innovation for crop and forage improvement and discusses database solutions for genebanks and germplasm collections. The book first looks at plant genetic resources and their values and goes on to investigate several genomic technologies for plant improvement, conservation, and better adaptation to changing climates. Major crops such as wheat and barley are discussed with genomic approaches for diversity and resilience to drought and other adverse conditions. Other omics techniques discussed include phenomics for the improvement of crop adaptation, metabolomics research for germplasm improvement and adaptation, and more. This volume will be valuable for researchers who are presently working in or with genebanks and genetic resources, primarily for trait or allele discovery and germplasm improvement. Most chapters in the book can also be used as teaching material at the undergraduate and postgraduate levels.
Cystic fibrosis used to be thought of as a respiratory and digestive disease, with a uniformly and rapidly fatal outcome. The spectrum of the disease has broadened into the mild atypical case, presenting in middle age, with the potential for complications in virtually every system of the body. In the past few years there has been an explosion of knowledge of the basic science of the defect. The editors have therefore invited the leading scientists and clinicians in the field of cystic fibrosis to describe the recent advances in this disease. Although there are many 'Recent Advances' texts, previous books have been selective in their choice of topics. This book is the first to cover the entire field of this complex disease, and encompasses the rapidly moving topics of the basic molecular and cellular biology as well as the recent multi-system, multi-disciplinary advances in the clinical care of patients. The authors have been charged with writing only about new developments and not to rehash old literature. The bulk of the references is therefore less than five years old. This book addresses all professionals who treat cystic fibrosis and want to have an up-date of new findings in the field, particularly of those outside their immediate specialisation. It will also be useful for basic researchers interested in related scientific areas and the clinical context of their work.